We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





POC Electrical Sensing-Based Blood Testing Technology Unveiled at ADLM 2024

By LabMedica International staff writers
Posted on 30 Jul 2024

Chronus Health (Fremont, CA, USA) is showcasing its innovative platform powered by electrical sensing-based blood testing technology at the ADLM 2024 conference taking place in Chicago from July 28 to August 1. More...

Chronus has developed the first-of-a-kind electrical sensing-based, real-time blood testing system for use in urgent care centers, skilled nursing facilities, infusion centers, retail clinics, as well as primary care and specialty clinics. This technology will reduce the time to diagnosis and lower overall healthcare costs since blood samples are analyzed on-site rather than sent to central labs for analysis. Chronus’ platform can uniquely support cell counting, chemistry assays (electrolytes, small molecules, and proteins), and immunoassays (proteins). This comprehensive solution, often regarded as the “holy grail” of diagnostics, has remained elusive until now, as past attempts to miniaturize existing technologies have lacked technical feasibility and cost-effectiveness.

The world’s first real-time electrical blood test system offers significant advantages in cost, size, and simplicity through the use of electrical sensors that facilitate miniaturization and reduce complexity. By leveraging a proprietary electrical sensing approach that integrates microfluidic sensors, machine learning, and aptamers, Chronus is poised to be the first to successfully deliver a platform capable of testing multiple blood panels outside the central lab setting. With 60% of all blood tests conducted outside hospitals, the company is at the forefront of providing fast and accurate blood testing at the point of care, at a lower price point.

“No one likes waiting for blood test results – neither doctors nor patients or their families,” said Caesar Djavaherian, MD, Co-Founder and Chief Clinical Innovation Officer of Carbon Health. “Now we have a technology that can cost-effectively provide results at the point of care, leading to better patient outcomes and increased provider satisfaction. We look forward to launching a clinical trial using the Chronus system soon.”

“We are creating a new era for point-of-care testing, with a platform slated to revolutionize the diagnostics industry,” said Anand Parikh, CEO and Co-Founder of Chronus Health. “The foundation of processing lab work has remained the same for decades, and just as other industries have benefited from the innovation in electrical technology, so too will healthcare.”

Related Links:
Chronus Health


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The LEX VELO system aims to redefine point-of-care testing (Photo courtesy of LEX Diagnostics)

POC System Delivers Lab-Quality PCR Results Directly from Swab Sample in Minutes

Medical and laboratory staff in primary care settings are multi-skilled and routinely multitask to deliver care with the speed and convenience expected of modern medicine. This places a strong requirement... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.